anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The HPV vaccine offers hope that the incidence of cervical cancer can be greatly reduced in the U.S. and globally. However, because the vaccine is recommended for children and early adolescents, vaccine awareness and acceptance among parents is critical to insuring vaccine uptake and public health benefit. Although culturally specific concerns may reduce HPV vaccination among African-American youth, research has not addressed this possibility. Accordingly, the proposed study will enroll 300 mothers in a study to identify barriers to HPV vaccination among low-income, African-American teens. Surveys assessing culturally-specific barriers to HPV vaccination acceptance will be administered to both parents and their vaccine-eligible children. Upon completion of the survey, parents with vaccine-eligible daughters will be invited to receive a free HPV vaccination for their child through a local, teen-friendly health clinic. Outcome analyses will focus on identification of predictors of completed vaccinations among girls and barriers to vaccine acceptance among mothers of teenage sons. Our study will provide critically important behavioral outcome data linking barriers to vaccination to subsequent vaccination decisions in a real-world, health care setting.
Fluid-weight management is critical for dialysis patients 1, 2. Previous clinical trials have not comprehensively addressed the application of a strategy combining both sodium restriction and a progressive, but gradual challenge of post dialysis target weight for BP and fluid-weight management in hemodialysis (HD). The investigators postulate that a protocolized, stepwise and gradual challenge of post-hemodialysis target weight when combined with diligent dietary sodium restriction \<2000mg sodium/day, will lead to better hydration/volume status and BP control in HD patients. A randomized, two parallel arm trial (n=40) among HD patients is proposed, that compares this comprehensive strategy in one group versus 'usual' HD volume/hydration and BP management in the control group. The two primary outcomes are change in volume/hydration status (assessed by bioelectrical impedance analysis-BIA) and change in BP (pre-dialysis in-center readings, home self-monitored readings as well as 44-hour interdialytic BP). Secondary outcomes include change in target post-dialysis weight, slope of on-line relative plasma volume monitoring (using Crit-line monitors), utilization and change, if any, in antihypertensive regimen, change in interdialytic weight gain, objectively assessed salt-appetite, thirst score, frequency of intradialytic hypotension, cramps and duration of post-dialysis fatigue and recovery, time to achievement of dry weight and laboratory parameters (hemoglobin, albumin, brain natriuretic peptide-BNP, aldosterone and hsCRP). The trial will be 14-weeks in duration and will involve comprehensive assessment of study parameters at baseline, middle and end of the trial. It is anticipated that the trial will lead to the the development of a simple and practical approach for volume and BP control in HD patients that will subsequently need to be studied on a larger scale, i.e., a larger, multicenter study with hard endpoints of death and hospitalization.
BACKGROUND: Standard treatment for eligible patients presenting with acute ischemic stroke (AIS) is thrombolysis with tissue plasminogen activators alteplase or tenecteplase. Current guidelines recommend monitoring patients in an intensive care unit (ICU) for 24 h after thrombolytic therapy. However, recent studies have questioned the need for prolonged ICU monitoring. This retrospective cohort study aims to identify potential candidates for early transition to a lower level of care by assessing risk factors for neurological deterioration, symptomatic intracranial hemorrhage (sICH), or need for ICU intervention within 24 h post-thrombolysis.
METHODS: This retrospective cohort study included adult patients 18 years and older with AIS who received thrombolysis. Patients were excluded if they were transferred to another facility, if they were transitioned to comfort care or hospice care within 24 h, or if they lacked imaging and National Institutes of Health Stroke Scale (NIHSS) score data. The primary end point was incidence of sICH between 0-12 and 12-24 h. Secondary end points included the need for ICU intervention and rates of neurological deterioration.
RESULTS: The analysis included 204 patients who received the full dose of alteplase. Among them, ten patients (4.9%) developed sICH, with the majority (n = 7) occurring within 12 h post-thrombolysis. Sixty-two patients required ICU interventions within 12 h compared with four patients after 12 h. Twenty-four patients had neurological deterioration within 12 h, and seven patients had neurological deterioration after 12 h. Multivariable analysis identified mechanical thrombectomy and increased blood pressure at presentation as predictors of ICU need beyond 12 h post-thrombolysis.
CONCLUSIONS: Our study demonstrates that sICH, neurological deterioration, and need for ICU intervention rarely occur beyond 12 h after thrombolytic administration. Patients presenting with blood pressures < 140/90 mm Hg, NIHSS scores < 10, and not undergoing mechanical thrombectomy may be best candidates for early de-escalation. Larger prospective studies are needed to more fully evaluate the safety, feasibility, and financial impact of early transition out of the ICU.
A low back pain relief device incorporating 8 harmonic patterns of mechanical stimulation (vibration) capable of neuromodulatory nociceptor block and vasodilation, and optional heat, cold, and pressure delivered through a sculpted metal plate attached with a belt and controlled by buttons on the belt. Patients will be instructed to use the device twice a day for 20 minutes.
BACKGROUND: In drug-induced liver injury, vascular endothelial progenitor cells, specifically the CD34+ cell fractions, have been found to decrease liver fibrosis and promote regeneration. However, it is unclear whether CD34+ cell transplantation has anti-fibrogenic effects on MASH, which has previously been treated effectively with anti-angiogenic therapy. We investigated the efficacy of ex vivo-expanded CD34+ cells in treating MASH livers.
MATERIALS AND METHODS: Diet-induced MASH mice were fed a choline-deficient, L-amino acid-defined, high-fat diet for 12 or 20 weeks, and were designated as a mild and a severe fibrosis model, respectively. Mouse bone marrow CD34+ cells were expanded for 7 days, transplanted into each mouse once or twice 2 weeks later, and sacrificed at 4 weeks after the first transplantation.
RESULTS: Expanded CD34+ cell transplantation ameliorated liver fibrosis, regardless of fibrosis degree, as indicated by the decrease in α-smooth muscle actin-positive cells, hydroxyproline concentration, and fibrogenic gene expression of Col1a1 and Timp1. Furthermore, engrafted CD34+ cells reduced alanine transaminase levels, the number of TUNEL+ hepatocytes, and 8-OHdG concentration. RNA-sequencing data showed that "defense response to virus" was the most down-regulated category in the Gene Ontology analysis and subsequent analysis revealed the suppression of RIG-I-like receptors/Irf7/Stat1/Cxcl10 axis in expanded CD34+ cell-transplanted livers. Finally, the downregulation of CXCL10 expression inhibits the mobilization of inflammatory immune cells, macrophages, T cells, and natural killer cells to the MASH liver.
CONCLUSIONS: These findings suggest that transplanted expanded CD34+ cells alleviate fibrotic liver injury in MASH mouse models through possible modulation of the innate immune response, which is abnormally activated by hepatocyte lipotoxicity.
NEW MATERIAL:A T-cell synthesis suppressing substance effective to suppress the DNA synthesis of T-cell. Elemental analysis, contains C, H, O, N and S; molecular weight, a peptide having a molecular weight of about 1,000 Dalton; thermal stability, stable at 56 deg.C for 1hr and 110 deg.C for 30min; nature, weakly basic; pH stability, stable at 4.0-9.5pH; ultraviolet absorption spectrum, absorption peak at 220nm; color reaction, positive to ninhydrin reaction; solubility, easily soluble in water, methanol and ethanol; color, colorless when dissolved in the above solvents. USE:Remedy for autoimmune diseases. Low side effects such as hypoadrenalism, leucopenia, etc. Applicable also as an antibacterial substance against Gram-negative bacteria. PREPARATION:The compound can be collected from mammal serum or the body fluid or cultured cell of insects such as silkworm moth, saturniid, flesh fly, honey-bee, etc.
Flavonoids are recovered from the ground seeds of Sylibum spp. by digesting the ground seeds (opt. after) extraction with a fat-solvent, pref. a halogenated hydrocarbon of specific gravity >1.35) with a strongly polar solvent; subsequently exhaustively extracting with acetone methanol or ethylacetate, purifying by an extraction (pref. countercurrent) with a system consisting of ethylacetate a polar solvent and aq. NaCl; subjecting the flavonoids to partition extraction with methanolic CaCl2, soln CaCl2-contg. ethylene glycol and hydrocarbons; precipitating the flavonoids in the form of a crude product by dispersing the extraction water; opt. crystallising the major flavonoids from a small amt of MeOH; opt. recrystallising from acetone/MeOH or methanolic CaCl2/water; and opt. separating flavonoids remaining in the mother liquor by column chromatography or fractional extraction. Silybum marianum is a medicinal plant used against liver disorders and gallstones.
The test days will consist of sitting in an infrared sauna cabin (HM-LSE-3 Professional edition, Health Mate, Belgium). Participants will sit in an infrared sauna at 21° Celsius for a total of 40 minutes.
Pre-local analgesia topical Benzocaine gel or Ethyl Chloride technique will be selected randomly and applied per the protocol. A single calibrated operator (A.A) using randomly selected sealed envelopes that have been previously divided equally according to sample size arms. The selected envelope is then opened by the operator, who applies either the EC or BC topical anesthesia technique based on the chosen envelop. Followed by maxillary local analgesia buccal infiltration for a single tooth by a calibrated operator (A.A). The child is then observed and assessed by the blinded primary investigator (N.A) (to the topical anesthesia technique) for pain perception during local anesthesia infiltration based on the Sound, Eye, Motor index used in this study. The child is then asked to rate the Visual Analog Scale and Facial Pain Scale. Heart rate of the patient will be recorded as per below protocol.
Provided is a biomarker capable of specifically diagnosing acute renal failure. The acute renal failure-specific biomarker is miRNA which is primarily present in blood. The miRNA is miRNA-5100. Furthermore, it is possible to use this miRNA-5100 as a method for diagnosing acute renal failure. When making a diagnosis, acute renal failure is diagnosed when miRNA-5100 expression in the blood decreases. As a kit for testing for acute renal failure, it is possible to include a reagent which measures miRNA-5100.
PRADAXA Capsules can be used in pediatric patients aged 8 to less than 18 years of age who are able to swallow the capsules whole. Other age-appropriate pediatric dosage forms of dabigatran etexilate are available for pediatric patients less than 8 years of age. For the treatment of VTE in pediatric patients, initiate treatment following treatment with a parenteral anticoagulant for at least 5 days. For reduction in risk of recurrence of VTE, initiate treatment following previous treatment. 

PRADAXA Capsules is dosed orally twice daily, one dose in the morning and one dose in the evening, at approximately the same time every day. The dosing interval should be as close to 12 hours as possible. 

The recommended dosage of PRADAXA Capsules for the treatment of or reducing the risk of VTE in pediatric patients 8 to less than 18 years of age is based on the patient's actual weight as shown in Table 1 below. Administer PRADAXA twice daily. Adjust the dosage according to actual weight as treatment progresses [see Dosage and Administration (2.5)].
In this arm, the study subject will first receive dronabinol 2.5 mg capsules. For two weeks the subject will titrate dose with one capsule corresponding to 2.5 mg dronabinol every other day until 20 mg. Doses are divided into three times a day. After up titration the subject will receive 20 mg daily treatment over a period of 2 weeks. After a wash out period of 2 weeks, study subject will receive placebo capsules (matching dronabinol 2.5 mg capsules). For two weeks the subject will titrate with one capsule every other day until 20 mg. Doses are divided into three times a day. After up titration the subject will receive 8 daily placebo capsules over a period of 2 weeks.
In the intervention group, MS women received a personalized daily eating plan (specific meals, recipes, food portions) together with nutritional consultation on the Meditteranean dietary pattern, as well as physical activity guidelines. All essential aspects of the dietary plan e.g. daily energy expenditure, classification of physical activity based on the concept of metabolic equivalent (MET), caloric adjustment according to nutritional status, and macronutrient distribution were calculated by a Clinical Decision Support System (CDSS). Body mass index (BMI) was also calculated, as the ratio of reported weight (kg) to the square of height (m2). Co-existed health issues, such as constipation or esophageal reflux, were taken into consideration. All MS patients acquired personal login passwords that allowed them to get access to their personal CDSS account and track their progress in regards to body weight, physical activity, and healthy food choices consumption.
PURPOSE: A composition containing an Ixeris dentata NaKai extract as an active ingredient for suppressing oral bacteria is provided to suppress the growth of Streptococcus mutans, generation of organic acid, and formation of a Streptococcus mutans biofilm, thereby preventing, alleviating, and treating dental diseases without side effects. CONSTITUTION: A composition for suppressing oral bacteria contains an Ixeris dentata NaKai extract as an active ingredient. The extract suppresses the growth of Streptococcus mutans, generation of organic acid by Streptococcus mutans, and formation of a Streptococcus mutans biofilm. A preventive and therapeutic agent for dental diseases for suppressing oral bacteria contains the extract as an active ingredient. The preventive and therapeutic agent is formulated in a unit dose form by adding a pharmaceutically acceptable carrier, excipient, or diluents. The preventive and therapeutic agent is manufactured in the form selected from a group consisted of an oral cleanser, a toothpaste, an oral spray, and a denture cleaner.
While prior work has investigated the benefits of online health communities and general-purpose social media used for health-related purposes, little work examines the use of TikTok, an emerging social media platform with a substantial user base. The platform's multimodal capabilities foster creative self-expression, while the content-driven network allows users to reach new audiences beyond their personal connections. To investigate users' challenges and motivations, we analyzed 160 TikTok videos that center on users' firsthand experiences living with chronic illness. We found that users struggled with a loss of normalcy and stigmatization in daily life. To contend with these challenges, they publicly shared their experiences to raise awareness, seek support from peers, and normalize chronic illness experiences. Based on our findings, we discuss the modalities of TikTok that facilitate self-expression around stigmatized topics and provide implications for the design of online health communities that better support adolescents and young adults.
Psoriasis is a chronic systemic inflammatory cutaneous disease. Where the immune system plays an important role in its pathogenesis, with key inflammatory intercellular signalling peptides and proteins including IL-17 and IL-23. The psychoneurological system also figures prominently in development of psoriasis. There is a high prevalence of comorbidity between psoriasis and mental health disorders such as depression, anxiety and mania. Patients with psoriasis often suffer from pathological pain in the lesions, and their neurological accidents could improve the lesions in innervated areas. The immune system and the psychoneurological system interact closely in the pathogenesis of psoriasis. Patients with psoriasis exhibit abnormal levels of neuropeptides both in circulating and localized lesion, acting as immunomodulators involved in the inflammatory response. Moreover, receptors for inflammatory factors are expressed in both peripheral and central nervous systems (CNSs), suggesting that nervous system can receive and be influenced by signals from immune system. Key inflammatory intercellular signalling peptides and proteins in psoriasis, such as IL-17 and IL-23, can be involved in sensory signalling and may affect synaptic plasticity and the blood-brain barrier of CNS through the circulation. This review provides an overview of the multiple effects on the peripheral and CNS under conditions of systemic inflammation in psoriasis, providing a framework and inspiration for in-depth studies of neuroimmunomodulation in psoriasis.
Chemotherapy with cisplatin is one of the most common treatments for patients with HNSCC, which could very possibly cause severe nausea and vomiting in last up to 5 days after administration of the drug. Nurses play an important role in managing CINV. The goal of this clinical trial is to investigate the effect of a nurse-led standardized intervention on chemotherapy induced nausea and vomiting (CINV) in patients with head and neck squamous cell carcinoma. The main questions it aims to answer are: (1) what's the best practice to enhance the management of CINV; (2) how's the effect of the nurse-led standardized intervention on CINV in the patients treated with cisplatin-based chemotherapy. Best practice to optimize CINV management for HNSCC patients who receive cisplatin-based chemotherapy have been instituted based on evidence. Participants in the intervention group will receive the evidence-based, nurse-led standardized management of CINV. Once the patient in the intervention group decide to undergo cisplatin-based chemotherapy, the nurses would assess the risk factors associated with chemotherapy-induced nausea and vomiting (CINV) and report to the physicians. During the chemotherapy, nurses will provide education on prevention and control of CINV using web-based approaches. All patients will receive standard antiemetic regimen, which includes Aprepitant, 5-HT3 RA, and Dexamethasone. If the physician's prescription are not accordance with the standard antiemetic regimen, nurse would remind the physician to adjust the prescription. Patients will be recommended to eat small and frequent meals slowly. Overly spicy, fatty, and sweet foods should be avoided. Music relaxation therapy will be performed for 60 min each time, once a day, and 3 times in the whole chemotherapy cycle. Follow-up will be delivered until the 5th day after chemotherapy. Guides on how to relieve nausea and vomiting will also be provided. Participants in the control group will receive routine care of CINV. Patients will be given drugs to prevent and control emesis according to the physicians' individual prescriptions. Nurses provide education about nausea and vomiting control and recommend patients to drink more water and eat light food. Patients will be given Metoclopramide when they are vomiting. The incidence and occurrence degree of CINV and its influence on patients' quality of life will be compared between the two groups.
Provided are an anti-SARS-Cov-2 nanobody and use thereof. The nanobody comprises CDR1, CDR2 and CDR3; the amino acid sequence of CDR1 is set forth in SEQ ID NO: 1, the amino acid sequence of CDR2 is set forth in SEQ ID NO: 2, and the amino acid sequence of CDR3 is set forth in SEQ ID NO: 3. Provided is a fusion protein, which is formed by the conjugation of the nanobody and an Fc, or by the conjugation of two or more nanobodies. The use refers to use of the nanobody or the fusion protein in the preparation of a drug for treating SARS-Cov-2. The nanobody has the potential to neutralize the Omicron strain, and has the advantages of small molecular weight, high binding activity, stable physical and chemical properties, ease of mass production, transport, storage, and the like. The nanobody can bind to RBDO and almost completely inhibits the binding of RBDO to ACE2, providing the foundations for the design and assembly of bispecific or even multispecific antibodies and CAR molecules.
NEW MATERIAL:A rabbit vitronectin-like protein having following properties; Moving as simple band in SDS-PAGE, having about 660000 molecular weight and having a structure in which 5-12th and 15-22th amino acid sequences are represented respectively by formulae I and II. USE:An antigen for production of a monoclonal antibody for recognition of focus of arteriosclerosis. PREPARATION:A cDNA library produced, e.g. from liver of Japanese white house rabbit is inserted into a coliform bacillus followed by cultivation. The partial amino acid sequence of a rabbit vitronectin-like protein is determined and a DNA corresponding to this sequence is synthesized. By using the synthesized DNA as a probe and carrying out screening, positive clones are selected. From the selected clones, a plasmid is extracted and a DNA coding the rabbit vitronectin-like protein is collected. The collected DNA is bonded to a vector and the host is transformed. The resultant transformant is then cultured, thus obtaining the objective rabbit vitronectin-like protein.
Sham protocol: it consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
PURPOSE: A pharmaceutical composition for controlling function of blood vessel contains cytokeratin-1 as an active ingredient. CONSTITUTION: A cytokeratin-1 protein is endothelial cells which recognize shearing stress inside blood vessel. The cytokeratin-1 protein contains an amino acid of sequence number 2 and DNA sequence of sequence number 1. A pharmaceutical composition for controlling blood vessel contains the cytokeratin-1 as an active ingredient. A pharmaceutical composition for preventing and treating arteriosclerosis contains the cytokeratin-1 protein as an active ingredient. A method for screening the cytokeratin-1 protein comprises: a step of lyzing a surface protein of endothelial cells to protease; a step of collecting the protein dissolved in a medium; a step of passing adsorption bead; a step of isolating a protein which is conjugated to the adsorption bead; a step of analyzing isolated protein with mass spectrograph to confirm protein existing in cell membrane; and a step of isolating cytokeratin-1.
Participants will receive a loading dose of 180 mg ticagrelor 1-3 days before stenting followed by a maintenance dose of 90 mg twice daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.